Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage

Tetsuaki Shoji; Hidenori Mizugaki; Yasuyuki Ikezawa; Megumi Furuta; Yuta Takashima; Hajime Kikuchi; Houman Goudarzi; Hajime Asahina; Junko Kikuchi; Eiki Kikuchi; Jun Sakakibara-Konishi; Naofumi Shinagawa; Ichizo Tsujino; Masaharu Nishimura

doi:10.2169/internalmedicine.9741-17

This article has now been updated. Please use the final version.

Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage

Tetsuaki Shoji, Hidenori Mizugaki, Yasuyuki Ikezawa, Megumi Furuta, Yuta Takashima, Hajime Kikuchi, Houman Goudarzi, Hajime Asahina, Junko Kikuchi, Eiki Kikuchi, Jun Sakakibara-Konishi, Naofumi Shinagawa, Ichizo Tsujino, Masaharu Nishimura

Author information

Tetsuaki Shoji
First Department of Medicine, Hokkaido University Hospital, Japan
Hidenori Mizugaki
First Department of Medicine, Hokkaido University Hospital, Japan
Yasuyuki Ikezawa
First Department of Medicine, Hokkaido University Hospital, Japan
Megumi Furuta
First Department of Medicine, Hokkaido University Hospital, Japan
Yuta Takashima
First Department of Medicine, Hokkaido University Hospital, Japan
Hajime Kikuchi
First Department of Medicine, Hokkaido University Hospital, Japan
Houman Goudarzi
First Department of Medicine, Hokkaido University Hospital, Japan
Hajime Asahina
First Department of Medicine, Hokkaido University Hospital, Japan
Junko Kikuchi
First Department of Medicine, Hokkaido University Hospital, Japan
Eiki Kikuchi
First Department of Medicine, Hokkaido University Hospital, Japan
Jun Sakakibara-Konishi
First Department of Medicine, Hokkaido University Hospital, Japan
Naofumi Shinagawa
First Department of Medicine, Hokkaido University Hospital, Japan
Ichizo Tsujino
First Department of Medicine, Hokkaido University Hospital, Japan
Masaharu Nishimura
First Department of Medicine, Hokkaido University Hospital, Japan

Keywords: lung cancer, venous thromboembolism, novel oral anticoagulants, direct oral anticoagulants, tumor shrinkage, tumor volume

JOURNAL OPEN ACCESS Advance online publication

Article ID: 9741-17

DOI https://doi.org/10.2169/internalmedicine.9741-17

The final version of this article is now available: Vol. 57 (2018), No. 12 pp. 1769-1772

Details

Abstract

This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.

Corresponding author

Register with J-STAGE for free!